Home What is Buprenorphine? DATA Physician Locator DATA 2000 FAQs Publications/Reports Links En Español Physician Waiver Qualifications Waiver Notification Form Upcoming Trainings Waived Physician WebBoard Update Physician Contact Information Model State Medical Board Policy Nurses Guide to Buprenorphine Email Us |
The Drug Addiction Treatment Act of 2000 (DATA 2000)The Drug Addiction Treatment Act of 2000 (DATA 2000) expands the clinical context of medication-assisted opioid addiction treatment by allowing qualified physicians to dispense or prescribe specifically approved Schedule III, IV, and V narcotic medications for the treatment of opioid addiction in treatment settings other than the traditional Opioid Treatment Program (i.e., methadone clinic). In addition, DATA 2000 reduces the regulatory burden on physicians who choose to practice opioid addiction therapy by permitting qualified physicians to apply for and receive waivers of the special registration requirements defined in the Controlled Substances Act. moreSAMHSA Sponsored Buprenorphine Physician Clinical Support System (PCSS)The SAMHSA-funded PCSS is a national network of trained physician mentors with expertise in buprenorphine treatment and skilled in clinical education designed to assist practicing physicians in incorporating into their practices the treatment of prescription opioid and heroin dependent patients using buprenorphine.www.pcssmentor.orgGet the Latest on Substance Abuse and Mental HealthDid you know that you can receive updates on materials and resources related to substance abuse and mental health issues? By enrolling in SAMHSA’s eNetwork, a free service, you can stay current with the latest grant announcements, data, and publications that will help you serve your community. Once you Join the eNetwork, you can choose your areas of interest and receive the information that is important to you.For example, we can send you regular email updates on:
Federal Register NoticeOn June 19, SAMHSA issued a notice of proposed rulemaking on the use of buprenorphine products in SAMHSA-certified opioid treatment programs (OTPs). If adopted, the proposal would remove the time in treatment dispensing requirements for buprenorphine products used to treat patients in OTPs. The dispensing restrictions would remain in effect for patients treated with methadone. The closing date for comments on this proposal is August 19, 2009. Use this link to view the notice.SAMHSA and DEA issue letter on prescribing Suboxone/Subutex in opioid treatment programsThis is in response to requests for clarification regarding a physician's authority, while employed by an Opioid Treatment Program (OTP) certified by the Substance Abuse and Mental Health Services Administration (SAMHSA) and registered with the Drug Enforcement Administration (DEA) as an Narcotic Treatment Program (NTP), (hereinafter OTP) to prescribe, write orders for, or dispense Suboxone® or Subutex® to patients for addiction/dependence treatment under the provisions of the Drug Addiction Treatment Act of 2000 (DATA 2000). Use this link to go to the letter.New Resource Available for Nurses on BuprenorphineThe Center for Substance Abuse Treatment (CSAT), Substance Abuse and Mental Health Services Administration (SAMHSA), is releasing a Technical Assistant Publication (TAP 30) titled "Buprenorphine: A Guide for Nurses." This publication is intended to provide nurses, including registered nurses (RNs), licensed practical nurses (LPNs), nurse practitioners (NPs), and Advanced Practice Nurses (APNs) with current information about buprenorphine products-Suboxone® (buprenorphine and naloxone) and Subutex® (buprenorphine)-for the pharmacological treatment of opioid addiction. This Guide can also serve as a resource to enable nurses working with physician prescribers to improve treatment outcomes for individuals receiving buprenorphine treatment for opioid addiction. Use this link to download the announcement. Use this link to download the nurses guide to buprenorphine.New Resource Available on Medication-Assisted Treatment for Opioid AddictionThe Substance Abuse and Mental Health Services Administration's (SAMHSA's) Center for Substance Abuse Treatment (CSAT) is pleased to announce the availability of Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs Inservice Training, a new training manual based on Treatment Improvement Protocol (TIP) 43. This new manual provides detailed training information aimed at introducing substance abuse treatment professionals to medication-assisted treatment for opioid addiction in opioid treatment programs. The manual describes opioid use disorders; provides assessment, treatment planning, pharmacology, and dosing information; and presents evidence-based best practices for treatment. Use this link to download a free copy.Results from New Clinical Trial of Buprenorphine in Young AdultsThis clinical trial evaluates the efficacy of continuing Buprenorphine-Naloxone for 12 weeks versus detoxification for opioid-addicted youth. The number of patients younger than 18 years was too small to analyze separately, but overall, patients in the detox group had higher proportions of opioid-positive urine test results at weeks 4 and 8 but not at week 12. Click here for link to JAMA Article.SAMHSA and NIDA Convene Summit on Buprenorphine TreatmentThe Summit convened February 21-22, 2008, in Washington, D.C. to bring together experts in epidemiology, pharmacology, toxicology, and addiction treatment in order to build upon the findings of the previous summits in 2003 and 2005. Participants assessed the successes, progress and continued barriers to access to opioid treatment with buprenorphine. Presentations identified best practices and useful clinical supports to enhance the quality of treatment. Participants identified strategies to address emerging issues and concerns. SAMHSA and NIDA will prepare a report on the proceedings.Use this HTML link to view presentations.Update Physician Contact InformationPhysicians, you can now update your own contact information. If you have given permission to post contact information in the Buprenorphine Physician and Treatment Program Locator, the information will be updated there too. Use this link to go to the update form.What's New Help with RSS |
Treatment Improvement Protocol Increase Patient Limits 2005 SAMHSA Evaluation of the Impact of the DATA Waiver Program 2006 Report On Diversion and Abuse of Buprenorphine Drug Enforcement Administraton (DEA) DATA Physician Locator SAMHSA and DEA issue letter on prescribing Suboxone/Subutex in opioid treatment programs CSAT Director Informs Physicians of Increase in Patient Limits CSAT Director Notifies Physicians of a New Feature to the SAMHSA Buprenorphine Physician and Treatment Program Locator CSAT Director Advises Physicians of Concerns Regarding Buprenorphine CSAT Director Encouraging Physicians to Sign-Up for the Buprenorphine Physician and Treatment Program Locator Follow this RealMedia link to view a Public Service Announcement (PSA) on office-based opioid addiction treatment featuring former Surgeon General Dr. C. Everett Koop. [Realplayer file, need Realplayer to review] If you do not have RealPlayer, you may download a free copy from Real Networks. |
Home | Accessibility | Privacy | Disclaimer | SAMHSA
Department of Health & Human Services | USA.gov * Adobe™ PDF formatted files require the Adobe™ Reader to properly read them. Use this link to download this FREE program. |